Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.64% | 1.88M | 97.97M |
| Vanguard Small-Cap Index Fund | 2.27% | 1.62M | 84.07M |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.05% | 1.46M | 76.14M |
| iShares Russell 2000 ETF | 1.93% | 1.37M | 71.49M |
| Vanguard Small-Cap Growth Index Fund | 1.34% | 954.02k | 49.6M |
| Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | 1.02% | 728.38k | 37.87M |
| Wasatch Small Cap Growth Fund | 0.95% | 677.34k | 35.22M |
| Vanguard Extended Market Index Fund | 0.92% | 654.69k | 34.04M |
| Invesco Small Cap Growth Fund | 0.86% | 612.49k | 31.84M |
| Wasatch Ultra Growth Fund | 0.82% | 583.12k | 30.32M |
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
10/17 08:30 am
GlobeNewswire Inc.
Read moreIs ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?
10/06 09:40 am
Zacks Investment Research
Read moreChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/05 08:30 am
GlobeNewswire Inc.
Read moreIs Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
09/26 06:20 am
Zacks Investment Research
Read moreIs SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
09/23 06:20 am
Zacks Investment Research
Read moreWhy Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?
09/08 11:30 am
Zacks Investment Research
Read moreWhy Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?
09/07 11:30 am
Zacks Investment Research
Read more2 Top Biotech Stocks to Buy for the Long Haul
08/24 08:40 am
The Motley Fool
Read moreChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences
08/24 08:30 am
GlobeNewswire Inc.
Read more3 Biopharmas on Buyout Watch
08/22 08:00 am
The Motley Fool
Read moreHas Moderna Made a Bear Market Blunder?
08/17 09:15 am
The Motley Fool
Read moreHere's Why ChemoCentryx (CCXI) is a Great Momentum Stock to Buy
08/16 12:00 pm
Zacks Investment Research
Read moreChemoCentryx (CCXI) Now Trades Above Golden Cross: Time to Buy?
08/16 09:55 am
Zacks Investment Research
Read moreThe Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals
08/12 06:05 am
Zacks Investment Research
Read moreBiotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates
08/11 11:25 am
Zacks Investment Research
Read moreGet ready for more merger mania in the pharma sector for the rest of the year
08/11 07:30 am
MarketWatch
Read moreBenzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
08/10 10:11 am
Benzinga
Read moreOcular Therapeutix (OCUL) Reports Q2 Loss, Lags Revenue Estimates
08/08 05:45 pm
Zacks Investment Research
Read moreWhere ChemoCentryx Stands With Analysts
08/05 12:02 pm
Benzinga
Read moreBenzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
08/05 10:43 am
Benzinga
Read more3 Analysts Have This to Say About ChemoCentryx
08/05 09:48 am
Benzinga
Read moreAmgen (AMGN) Beats Q2 Earnings Estimates, to Buy Chemocentryx
08/05 09:45 am
Zacks Investment Research
Read moreChemoCentryx (CCXI) Moves 109.2% Higher: Will This Strength Last?
08/05 07:29 am
Zacks Investment Research
Read moreWhy NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
08/05 06:12 am
Benzinga
Read moreCoinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday
08/05 04:00 am
Benzinga
Read moreGold Tops 1,800; Alibaba Reports Upbeat Results
08/04 02:48 pm
Benzinga
Read moreWhy ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session
08/04 01:12 pm
Benzinga
Read moreNasdaq Edges Higher; Crude Oil Falls Sharply
08/04 12:06 pm
Benzinga
Read moreDow Drops Over 100 Points; U.S. Trade Deficit Shrinks To This Level In June
08/04 10:44 am
Benzinga
Read moreWhy ChemoCentryx Stock Is On Fire Today
08/04 10:08 am
The Motley Fool
Read moreWill Brickell (BBI) Report Negative Earnings Next Week? What You Should Know
08/04 10:00 am
Zacks Investment Research
Read moreChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022
08/02 04:05 pm
GlobeNewswire Inc.
Read moreChemoCentryx's (CCXI) Tavneos Aids Growth, Overdependence a Woe
07/05 12:53 pm
Zacks Investment Research
Read moreChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director
07/05 08:30 am
GlobeNewswire Inc.
Read moreCatalyst (CPRX) Up 6.9% Since Last Earnings Report: Can It Continue?
06/09 11:30 am
Zacks Investment Research
Read moreChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences
05/31 04:05 pm
GlobeNewswire Inc.
Read moreChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa
05/18 08:30 am
GlobeNewswire Inc.
Read moreChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
05/16 08:30 am
GlobeNewswire Inc.
Read moreChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis
05/11 08:30 am
GlobeNewswire Inc.
Read moreChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates
05/06 03:38 pm
Zacks Investment Research
Read moreChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates
05/05 06:35 pm
Zacks Investment Research
Read moreWill ChemoCentryx (CCXI) Report Negative Q1 Earnings? What You Should Know
04/28 03:02 pm
Zacks Investment Research
Read moreChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022
04/13 08:30 am
GlobeNewswire Inc.
Read moreWhy Is ChemoCentryx (CCXI) Up 1.8% Since Last Earnings Report?
03/31 11:30 am
Zacks Investment Research
Read more2 Stocks Down 30% in 2022 That Are Great Buys Right Now
03/30 11:30 am
The Motley Fool
Read moreSee Why Is Stifel Analyst 'Perplexed' After ChemoCentryx Q4 Earnings
03/02 02:51 pm
Benzinga
Read moreChemoCentryx (CCXI) Q4 Earnings and Sales Miss Estimates
03/02 11:33 am
Zacks Investment Research
Read moreThe Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
03/02 08:50 am
Benzinga
Read moreChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates
03/01 06:35 pm
Zacks Investment Research
Read moreThe Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
03/01 08:51 am
Benzinga
Read more